These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

416 related items for PubMed ID: 30779980

  • 1. Anisamide-targeted PEGylated gold nanoparticles designed to target prostate cancer mediate: Enhanced systemic exposure of siRNA, tumour growth suppression and a synergistic therapeutic response in combination with paclitaxel in mice.
    Luan X, Rahme K, Cong Z, Wang L, Zou Y, He Y, Yang H, Holmes JD, O'Driscoll CM, Guo J.
    Eur J Pharm Biopharm; 2019 Apr; 137():56-67. PubMed ID: 30779980
    [Abstract] [Full Text] [Related]

  • 2. Anisamide-targeted gold nanoparticles for siRNA delivery in prostate cancer - synthesis, physicochemical characterisation and in vitro evaluation.
    Fitzgerald KA, Rahme K, Guo J, Holmes JD, O'Driscoll CM.
    J Mater Chem B; 2016 Apr 07; 4(13):2242-2252. PubMed ID: 32263220
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Development of anisamide-targeted PEGylated gold nanorods to deliver epirubicin for chemo-photothermal therapy in tumor-bearing mice.
    Wang L, Pei J, Cong Z, Zou Y, Sun T, Davitt F, Garcia-Gil A, Holmes JD, O'Driscoll CM, Rahme K, Guo J.
    Int J Nanomedicine; 2019 Apr 07; 14():1817-1833. PubMed ID: 30880982
    [Abstract] [Full Text] [Related]

  • 5. Bioconjugated Gold Nanoparticles Enhance siRNA Delivery in Prostate Cancer Cells.
    Rahme K, Guo J, Holmes JD.
    Methods Mol Biol; 2019 Apr 07; 1974():291-301. PubMed ID: 31099011
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of the physicochemical properties and the biocompatibility of polyethylene glycol-conjugated gold nanoparticles: A formulation strategy for siRNA delivery.
    Rahme K, Guo J, Holmes JD, O'Driscoll CM.
    Colloids Surf B Biointerfaces; 2015 Nov 01; 135():604-612. PubMed ID: 26322474
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A novel, anisamide-targeted cyclodextrin nanoformulation for siRNA delivery to prostate cancer cells expressing the sigma-1 receptor.
    Fitzgerald KA, Malhotra M, Gooding M, Sallas F, Evans JC, Darcy R, O'Driscoll CM.
    Int J Pharm; 2016 Feb 29; 499(1-2):131-145. PubMed ID: 26721726
    [Abstract] [Full Text] [Related]

  • 9. Smart polymeric nanoparticles with pH-responsive and PEG-detachable properties for co-delivering paclitaxel and survivin siRNA to enhance antitumor outcomes.
    Jin M, Jin G, Kang L, Chen L, Gao Z, Huang W.
    Int J Nanomedicine; 2018 Feb 29; 13():2405-2426. PubMed ID: 29719390
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Bioinspired tumor-homing nanoplatform for co-delivery of paclitaxel and siRNA-E7 to HPV-related cervical malignancies for synergistic therapy.
    Xu C, Liu W, Hu Y, Li W, Di W.
    Theranostics; 2020 Feb 29; 10(7):3325-3339. PubMed ID: 32194871
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Development of small interfering RNA delivery system using PEI-PEG-APRPG polymer for antiangiogenic vascular endothelial growth factor tumor-targeted therapy.
    Lu ZX, Liu LT, Qi XR.
    Int J Nanomedicine; 2011 Feb 29; 6():1661-73. PubMed ID: 21904456
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.